Skip to main content
. 2022 Jan 29;62:52–60. doi: 10.1016/j.breast.2022.01.014

Fig. 5.

Fig. 5

PFS by AURKA molecular alteration. (A) mutation. (B) amplification. (C) any mutation or amplification and (D) BRIP1 amplification. (E) MYC amplification. (F) RAD51C amplification. (G) HRR loss of function in palbociclib plus ET treated patients.